HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206

Role for the p53 homologue p73 in E2F-1-induced apoptosis

Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708

Inactivation of the p53 pathway in retinoblastoma

Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595

AIS is an oncogene amplified in squamous cell carcinoma

Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., & Sidransky, D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5462 · Cited by 464

p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis

Rocco, J. W., Leong, C., Kuperwasser, N., DeYoung, M. P., & Ellisen, L. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.013 · Cited by 435

Chemosensitivity linked to p73 function

Irwin, M. S., Kondo, K., Marín, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 406

MDM2, an introduction.

Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 390

MDM2 suppresses p73 function without promoting p73 degradation

Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334

P63 and P73 Activation in Cancers with p53 Mutation

Cai, B., Hsu, Y.-C., Yeh, F.-Y., Lin, Y.-R., Lu, R.-Y., Yu, S.-J., Shaw, J., Wu, M.-H., Tsai, Y.-Z., Lin, Y.-C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071490 · Cited by 24

Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

Al-Hussaini, M., & DiPersio, J. F. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.932687 · Cited by 26

MDM2-Mediated p21 Proteasomal Degradation Promotes Fluoride Toxicity in Ameloblasts

Deng, H., Ikeda, A., Cui, H., Bartlett, J. D., & Suzuki, M. (2019) · Cells · doi:10.3390/cells8050436 · Cited by 24

p73 expression is regulated by ribosomal protein RPL26 through mRNA translation and protein stability

Zhang, M., Zhang, J., Yan, W., & Chen, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13126 · Cited by 23

Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73

Canning, P., von Delft, F., & Bullock, A. N. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.005 · Cited by 22

p73 Plays a Role in Erythroid Differentiation through GATA1 Induction

Marqués-García, F., Ferrándiz, N., Fernández-Alonso, R., González-Cano, L., Herreros‐Villanueva, M., Rosa‐Garrido, M., Fernández‐García, B., Vaque, J. P., Marqués, M. M., Alonso-Ferrero, M. E., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.026849 · Cited by 22

p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies

Horvat, A., Tadijan, A., Vlašić, I., & Slade, N. (2021) · Cancers · doi:10.3390/cancers13122885 · Cited by 22

Reactivation of p53 via MDM2 inhibition

Kim, E. S., & Shohet, J. M. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.302 · Cited by 21

Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Patel, A. A., García, L. F., Mannella, V., Gammon, L., Borg, T., Maffucci, T., Scatolini, M., Chiorino, G., Vergani, E., Rodolfo, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3230 · Cited by 22

TP53 in AML and MDS: The new (old) kid on the block

Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20

p53 Family: Therapeutic Targets in Neuroblastoma

Wolter, J. K., Angelini, P., & Irwin, M. S. (2010) · Future Oncology · doi:10.2217/fon.09.176 · Cited by 22

Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re‐entry and p53 induction

Sulg, M., Kirjavainen, A., Pajusola, K., Büeler, H., Ylikoski, J. S., Laiho, M., & Pirvola, U. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06563.x · Cited by 19

Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway

Lee, S., Choi, H. C., Choe, Y.-J., Shin, S. J., Lee, S. H., & Kim, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2463 · Cited by 18

Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing

Zawacka‐Pankau, J. (2020) · Cancers · doi:10.3390/cancers12092717 · Cited by 16

Low‐dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin‐3 in gynecologic cancers

Ohgami, T., Kato, K., Kobayashi, H., Sonoda, K., Inoue, T., Yamaguchi, S., Yoneda, T., & Wake, N. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01543.x · Cited by 17

Targeting of p53 and its homolog p73 by protoporphyrin IX

Sznarkowska, A., Maleńczyk, K., Kadziński, L., Bielawski, K. P., Banecki, B., & Zawacka‐Pankau, J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.004 · Cited by 17

The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer

Fregni, M., Ciribilli, Y., & Zawacka‐Pankau, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137213 · Cited by 16

Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death

Marcus, J. M., Burke, R. T., Doak, A. E., Park, S., & Orth, J. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1480224 · Cited by 17

Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53

Choe, Y.-J., Lee, S.-Y., Ko, K. W., Shin, S. J., & Kim, H.-S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2227 · Cited by 16

p53 family interactions and yeast: together in anticancer therapy

Gomes, S., Leão, M., Raimundo, L., Ramos, H., Soares, J., & Saraiva, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.007 · Cited by 18

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation

Suleymanova, N., Crudden, C., Worrall, C., Dricu, A., Girnita, A., & Girnita, L. (2017) · Oncotarget · doi:10.18632/oncotarget.19286 · Cited by 15

Studying p53 family proteins in yeast: Induction of autophagic cell death and modulation by interactors and small molecules

Leão, M., Gomes, S., Bessa, C., Soares, J., Raimundo, L., Monti, P., Fronza, G., Pereira, C., & Saraiva, L. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.09.028 · Cited by 15

Treatment of Ovarian Cancer Cells with Nutlin-3 and Resveratrol Combination Leads to Apoptosis via Caspase Activation

Marimuthu, P., Kaur, K., Kandalam, U., Jasani, V., Bukhari, N., Nguyen, M., Abdul, A., Pervez, F. F., & Rathinavelu, A. (2010) · Journal of Medicinal Food · doi:10.1089/jmf.2009.0270 · Cited by 14

Emerging therapeutic targets for retinoblastoma

Manukonda, R., Narayana, R. V. L., Kaliki, S., Mishra, D. K., & Vemuganti, G. K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2158812 · Cited by 13

Kinase activity-independent suppression of p73α by AMP-activated kinase α (AMPKα)

Lee, Y.-G., Lee, S.-W., Sin, H.-S., Kim, E., & Um, S.-J. (2008) · Oncogene · doi:10.1038/onc.2008.452 · Cited by 13

Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells

Sznarkowska, A., Kostecka, A., Kawiak, A., Acedo, P., Lion, M., Inga, A., & Zawacka‐Pankau, J. (2018) · Cell Division · doi:10.1186/s13008-018-0043-3 · Cited by 13

Combination treatment with auranofin and nutlin-3a induces synergistic cytotoxicity in breast cancer cells

Ye, D.-J., Kwon, Y., Baek, H., Cho, E.-A., Kwon, T.-U., & Chun, Y. (2019) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2019.1635934 · Cited by 13

An Effective Virtual Screening Protocol To Identify Promising p53–MDM2 Inhibitors

Tortorella, P., Laghezza, A., Durante, M., Gomez-Monterrey, I. M., Bertamino, A., Campiglia, P., Loiodice, F., Daniele, S., Martini, C., & Agamennone, M. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00747 · Cited by 12

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation

Zheng, T., Wang, J., Chen, X., Meng, X., Song, X., Lu, Z., Jiang, H., & Liu, L. (2010) · Tumor Biology · doi:10.1007/s13277-010-0035-7 · Cited by 11

p53 in the Clinics

Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10

Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53

Abrams, S. L., Akula, S. M., Steelman, L. S., Follo, M. L., Cocco, L., Ratti, S., Martelli, A. M., Libra, M., Falzone, L., Candido, S., et al. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2021.100840 · Cited by 10

E2F1‐dependent pathways are involved in amonafide analogue 7‐d‐induced DNA damage, G2/M arrest, and apoptosis in p53‐deficient K562 cells

Li, Y., Shao, J., Shen, K., Xu, Y. F., Liu, J., & Qian, X. H. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24194 · Cited by 9

Dual-channel surface plasmon resonance monitoring of intracellular levels of the p53-MDM2 complex and caspase-3 induced by MDM2 antagonist Nutlin-3

Wu, L., Hu, Y., He, Y., Xia, Y., Lu, H., Cao, Z. Y., Yi, X., & Wang, J. (2019) · The Analyst · doi:10.1039/c9an00301k · Cited by 9

HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma

Shi, Y., Takenobu, H., Kurata, K., Yamaguchi, Y., Yanagisawa, R., Ohira, M., Koike, K., Nakagawara, A., Jiang, L., & Kamijo, T. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.026 · Cited by 9

Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells

Zhang, L., Yan, Y., Zhu, D., Yang, W., Wang, W., Hu, Y., Yang, B., & He, Q. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9512-5 · Cited by 8

Analyses of p73 Protein Oligomerization and p73–MDM2 Interaction in Single Living Cells Using In Situ Single Molecule Spectroscopy

Li, F., Du, Z., Huang, X., Dong, C., & Ren, J. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03521 · Cited by 9

Small‐molecule MDM2 inhibitor LQFM030‐induced apoptosis in p53‐null K562 chronic myeloid leukemia cells

Ribeiro, H. D. O., Cortez, A. P., de Ávila, R. I., da Silva, A. C. G., de Carvalho, F. S., Menegatti, R., Lião, L. M., & Valadares, M. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12540 · Cited by 8

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer

On, J. L., Ghaderi, S., Rittmann, C., Hoffmann, G., Gier, F., Woloschin, V., Tu, J., Bhatia, S., Kulik, A., Niederacher, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031078 · Cited by 7

A novel anti-cancer mechanism of Nutlin-3 through downregulation of Eag1 channel and PI3K/AKT pathway

Wang, X., Chen, Y., Liu, H., Guo, S., Hu, Y., Zhan, Y., & An, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.106 · Cited by 7

Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation

Mochizuki, H., Goto‐Koshino, Y., Sato, M., Fujino, Y., Ohno, K., & Tsujimoto, H. (2012) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2012.04.017 · Cited by 6

P53 gene: major mutations in neoplasias and anticancer gene therapy

Lima, C. R. D. O., Rabelo, R. E., Vulcani, V. A. S., Cardoso, L. D., Sousa, N. L. D. M., & de Moura, V. M. B. D. (2012) · Ciência Rural · doi:10.1590/s0103-84782012000500014 · Cited by 6

Programmed Cell Death in the Gastrointestinal Tract

Johnson, L. R., & Ray, R. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00013-0 · Cited by 7

Therapeutic considerations for Mdm2: not just a one trick pony

Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 6

Recruiting TP53 to target chronic myeloid leukemia stem cells

Grant, S. (2020) · Haematologica · doi:10.3324/haematol.2019.246306 · Cited by 5

ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN ‐Amplified Neuroblastoma

Lai, X., Yoda, H., Qiao, Y., Kida, Y., Takenaga, K., Shinozaki, Y., Koshikawa, N., & Takatori, A. (2025) · Cancer Science · doi:10.1111/cas.70043 · Cited by 4

Targeting MDM2 affects spastin protein levels and functions: implications for HSP treatment

Sardina, F., Polverino, F., Valentini, S., Carsetti, C., Falvo, E., Tisci, G., Soddu, S., Moretti, F., Paiardini, A., & Rinaldo, C. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02333-y · Cited by 3

The effects of Nutlin‐3 on morphology, cellular proliferation, and apoptosis in rat primary mesenchymal stem cells

Bajelan, B., Zaki‐Dizaji, M., Darabi, S., & Rajaei, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27798 · Cited by 3

TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds

Chakraborty, R., Dutta, A., & Mukhopadhyay, R. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03841-6 · Cited by 3

Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer

Peirce, S. K. (2010) · Cell Health and Cytoskeleton · doi:10.2147/chc.s4952 · Cited by 3

MDM2 inhibitor induces apoptosis in colon cancer cells through activation of the CHOP-DR5 pathway, independent of p53 phenotype

Lu, M., Ren, Y., Feng, S., Wang, S., Xia, W., Gu, B., Shen, Y., Yue, A., Li, N., Zhang, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1508421 · Cited by 2

p53-Reactivating Molecules as Research Tools and Anticancer Drugs

Grinkevich, V. V., Warnecke, A., & Selivanova, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_13 · Cited by 2

Systematic Characterization of p53-Regulated Long Noncoding RNAs across Human Cancers Reveals Remarkable Heterogeneity among Different Tumor Types

Regunath, K., Fomin, V., Liu, Z., Wang, P., Hoque, M., Tian, B., Rabadán, R., & Prives, C. L. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0295 · Cited by 2

Mechanisms and Ways to Overcome Acquired Resistance of Cancer Cells to Mcl-1 Antagonists

Pervushin, N. V., Fernandez, B. Y. V., Senichkin, V. V., Yapryntseva, M. A., Pavlov, V., Zhivotovsky, B., & Kopeina, G. S. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297925602710 · Cited by 1

BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer

Wang, L.-Y., Xu, X., Xuan, W.-J., Bi, X.-Y., & Zhou, Q. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01788-8 · Cited by 1

MOLECULAR GENETICS OF SOFT TISSUE TUMORS

Lasota, J. P. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781049.006 · Cited by 1

Resistance of human primary mesenchymal stem cells to cytotoxic effects of nutlin‐3 in vitro

Bajelan, B., Zaki‐Dizaji, M., Rahmani, B., Darzi, S., Darabi, S., & Rajaei, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29324 · Cited by 1

Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: potential for therapeutic intervention?

Schwaller, J. (2020) · Haematologica · doi:10.3324/haematol.2019.246348 · Cited by 1

Targeting the Transcription Factors of ROS Tumorigenic Pathways as a Therapeutic Strategy in Cancer

Sriramajayam, K., Gokulan, R. C., & Tharmalingam, J. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_275 · Cited by 1

Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP 53-deficient cancer cellsPreprint

Sznarkowska, A., Kostecka, A., Kawiak, A., Acedo, P., Lion, M., Inga, A., & Zawacka‐Pankau, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/357293 · Cited by 1

IKKalpha mediated NOTCH1 Activation Promotes Tumorigenesis via FOXA2 Suppression

Liu, M. (2012) · Digital Commons-TMC (Texas Medical Center)

Pharmacological targeting of mutant p53 family members

Rökaeus, N. (2011) · Figshare

Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts

Hofmann, L. (2007)

Phospho-regulation and metastatic potential of Murine Double Minute 2

Batuello, C. N. (2012) · doi:10.7912/c2/1866

Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin

Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308

p73 gene and its role in gynecological tumors: an advance

Peng, P., Huang, L., & Wang, Y. (2011) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2011.00334

Role of p53 in Apoptosis and Cancer Therapy

Daloii, M. R. N., & Abdollahzade, R. (2014) · مجله علمی پژوهشی افق دانش

Regulation of MDM2 and the p53 Family by the NEDD8 Pathway

Watson, I. R. (2011) · TSpace (University of Toronto)

Characterization of synthetic lethality between Mdm2 overexpression and genotoxic agents and identification of a novel function of the Mdmx oncogene in DNA repair

Carrillo, A. M. (2014)

Investigation of the intrinsic mechanism of drug resistance in multiple myeloma

Ooi, M. G. M. (2011) · Dublin City University Open Access Institutional Repository (Dublin City University)

Eixo p53-hHR23B-XPC na modulação das vias de reparo de DNA em melanomas: Evidências para processos de carcinogênese, progressão e quimioresistência

Francisco, G. (2015) · doi:10.11606/t.5.2015.tde-13052015-103235

Targeting the Transcription Factors of ROS Tumorigenic Pathways as a Therapeutic Strategy in Cancer

Sriramajayam, K., Gokulan, R. C., & Tharmalingam, J. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_275-1

Latest advances in cell-death pathway approaches in treating high-risk neuroblastoma

Temirbek, A., & Then, S. (2022) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v5i3.147

Molecular genetics of soft tissue tumors

Lasota, J. P. (2016) · Cambridge University Press eBooks · doi:10.1017/9781107707504.006

Synthesis and Mechanism of p53‐MDM2 Inhibitors with Heterocyclic Structures: A Focused Review

Ji, L., Zhang, W., Zhang, Y., Zhao, S., Long, H., Qin, L., Tian, J., Li, H., Zhu, D., Zhou, Y., et al. (2023) · ChemistrySelect · doi:10.1002/slct.202302240

Development of a Bipyrimidineamide based α-Helix Mimetic Lead Compound for efficient Targeting of MDM2 in Triple-Negative Breast CancerPreprint

On, J. L., Woloschin, V., Gier, F., Tu, J., Bhatia, S., Lenz, T., Kulik, A., Stühler, K., Niederacher, D., Neubauer, H. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.02.582899

Analysis of the molecular mechanism of claudin-1 expression in SCCKN cells, oral squamous cell carcinoma cell line

Nobumoto, T., Yamasaki, S., Hamada, A., Higaki, M., Ito, N., Obayashi, F., Ishida, Y., Hamana, T., Shintani, T., Tani, R., et al. (2024) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2024.12.017

Biomass-based enantioselective approach to 1,2-di(furan-2-yl)ethane-1,2-diamine and its derivatives

Vasechkin, K. V., Kovalevsky, R. A., Kucherenko, A. S., Romanenko, A. R., Korlyukov, A. A., & Zlotin, S. G. (2025) · Mendeleev Communications · doi:10.71267/mencom.7871

PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugsPreprint

Simón-Carrasco, L., Raya, S., Pietrini, E., Luque-Perez, M., Oliva, M. D. R., Rosado, I., & Lopez-Contreras, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.698947

"BH3-only" Noxa, cible spécifique de l'induction d'apoptose pour la thérapie des leucémies lymphoïdes chronique

Zaher, M. (2011) · theses.fr (ABES) · doi:10.70675/ebe78adcz9cd7z41b0zaff6z48ab13fa68ae

Expression et fonctions biologiques de l’isoforme ΔNp63

de Gasperis, A. (2011) · theses.fr (ABES) · doi:10.70675/3b754ccbz3f14z4949z9f45z1bdd5995d3d3

The role of p53 modulation in correcting aberrant placental apoptosis in pre-eclampsia and IUGR

Sharp, A. (2011) · Research Explorer (The University of Manchester)

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189

Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma

Drakos, E., Thomaides, A. X., Medeiros, L. J., Jiang, L., Leventaki, V., Konopleva, M. Y., Andreeff, M., & Rassidakis, G. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2581 · Cited by 98

Hdmx Modulates the Outcome of P53 Activation in

Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2013)

Hdmx modulates the outcome of p53 activation in human tumor cells

Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 89